Vimarsana
Biggest News Aggregation in the World

Page 2 - Loss Applicable News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Loss Applicable. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Loss Applicable Today - Breaking & Trending Today

Sigma Additive Solutions Reports Second Quarter 2022 Financial Results - Vimarsana News

Sigma Additive Solutions Reports Second Quarter 2022 Financial Results

Management to Host Conference Call Today at 8:30 a.m. ETSANTA FE, NM / ACCESSWIRE / August 5, 2022 / Sigma Additive Solutions (NASDAQ:SASI) ("Sigma"), a leading developer of quality assurance software

LogicMark, Inc. Announces First Quarter 2022 Financial and Operational Results - Vimarsana News

LogicMark, Inc. Announces First Quarter 2022 Financial and Operational Results

/PRNewswire/ -- LogicMark, Inc. (Nasdaq: LGMK) (the "Company" or "LogicMark") (formerly Nxt-ID, Inc.), a provider of personal emergency response systems...

LogicMark, Inc. Announces First Quarter 2022 Financial and Operational Results - Vimarsana News

LogicMark, Inc. Announces First Quarter 2022 Financial and Operational Results

/PRNewswire/ -- LogicMark, Inc. (Nasdaq: LGMK) (the "Company" or "LogicMark") (formerly Nxt-ID, Inc.), a provider of personal emergency response systems...

Sigma Labs, Inc.: Sigma Labs Reports First Quarter 2022 Financial Results - Vimarsana News

Sigma Labs, Inc.: Sigma Labs Reports First Quarter 2022 Financial Results

Management to Host Conference Call Today at 4:30 p.m. ETSANTA FE, NM / ACCESSWIRE / April 26, 2022 / Sigma Labs, Inc. (NASDAQ:SGLB) (the "Company" or "Sigma Labs"), a leading developer of quality assurance

Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2021 Financial Results and Provides Business Update - Vimarsana News

Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2021 Financial Results and Provides Business Update

/PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development...